Seeking Alpha

Amarin (AMRN +3.7%) is very close to receiving a long-sought patent on its lead drug candidate,...

Amarin (AMRN +3.7%) is very close to receiving a long-sought patent on its lead drug candidate, AMR101, after the USPTO issues a Notice of Allowance supporting the use of the fish-oil heart pill in patients with high triglycerides. A Notice of Allowance is typically issued after regulators decide that a patent can be granted from an application. Next up is an FDA decision on AMR101, expected this month. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|